VEDL Stock Recent News
VEDL LATEST HEADLINES
MUMBAI, India--(BUSINESS WIRE)---- $VEDL #Annualrevenue--Indian multinational Vedanta Limited (“Vedanta”) announced its results for Q4 and the financial year ending March 31, 2025.
Vedanta Resources, a mining conglomerate led by Indian tycoon Anil Agarwal, is weighing a US public listing for its Zambian unit Konkola Copper Mines (KCM) to raise $1 billion for mine development, according to a Reuters report. The report, which cited three sources with knowledge of the matter, said the company has engaged Barclays and Citigroup to advise on a potential initial public offering (IPO), with New York being considered as a possible listing venue.
Vedanta Resources, is considering a U.S. public listing for its Zambian unit Konkola Copper Mines as one of its options to try to raise about $1 billion for mine development, three sources familiar with the details, told Reuters.
TAIPEI, Taiwan--(BUSINESS WIRE)---- $VEDL #AvanstrateInc--AvanStrate Inc. Launches Game-Changing Display Glass That Enables 95% Reduction in Carbon Emissions.
MUMBAI, India--(BUSINESS WIRE)---- $VEDL #Aluminium--Vedanta's shareholders and creditors strongly endorse its demerger proposal with over 99% favorable votes.
MUMBAI, India--(BUSINESS WIRE)---- $VEDL #Aluminiumbusiness--Vedanta reports its highest-ever 3rd quarter EBITDA of ₹112.8 bn, + 30% YoY with a margin of 34%, up 517 bps YoY.
BOSTON--(BUSINESS WIRE)--PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine.
Vedanta (VEDL) share price has done well this year even as the prices of key commodities like iron ore, aluminum, and copper retreated. It soared to a record high of ₹470.60, meaning that it has jumped by over 1,453% from its lowest point in 2020.
UK-based Vedanta Resources, parent of India's Vedanta , has settled dues worth $245.75 million to help revive operations in Konkola copper mines (KCM) in Zambia as part of a deal to take back the mines, the Indian miner said on Friday.
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study of VE303.